Although some studies suggest that HER2-positive CRC cases carry a poor prognosis, some clinical trials targeting the HER2 pathway have shown promising results, in which dual HER2 blockade with MABs (trastuzumab with pertuzumab) or the combination of MABs with tyrosine kinase inhibitors (trastuzumab with lapatinib) induced durable tumor response in about one-third of patients refractory to standard systemic therapy [16]. This evidence concerns the gene ERBB2 and neoplasm.